Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1991 2
1992 2
1993 8
1994 8
1995 5
1997 5
1998 9
1999 5
2000 3
2001 1
2002 4
2003 3
2004 2
2005 1
2006 5
2007 1
2008 1
2009 3
2010 5
2011 3
2012 4
2013 6
2014 6
2015 8
2016 7
2017 12
2018 12
2019 7
2020 10
2021 5
2022 6
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Results by year

Filters applied: . Clear all
Page 1
Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.
Ozelo MC, Mahlangu J, Pasi KJ, Giermasz A, Leavitt AD, Laffan M, Symington E, Quon DV, Wang JD, Peerlinck K, Pipe SW, Madan B, Key NS, Pierce GF, O'Mahony B, Kaczmarek R, Henshaw J, Lawal A, Jayaram K, Huang M, Yang X, Wong WY, Kim B; GENEr8-1 Trial Group. Ozelo MC, et al. Among authors: peerlinck k. N Engl J Med. 2022 Mar 17;386(11):1013-1025. doi: 10.1056/NEJMoa2113708. N Engl J Med. 2022. PMID: 35294811 Clinical Trial.
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.
Pipe SW, Leebeek FWG, Recht M, Key NS, Castaman G, Miesbach W, Lattimore S, Peerlinck K, Van der Valk P, Coppens M, Kampmann P, Meijer K, O'Connell N, Pasi KJ, Hart DP, Kazmi R, Astermark J, Hermans CRJR, Klamroth R, Lemons R, Visweshwar N, von Drygalski A, Young G, Crary SE, Escobar M, Gomez E, Kruse-Jarres R, Quon DV, Symington E, Wang M, Wheeler AP, Gut R, Liu YP, Dolmetsch RE, Cooper DL, Li Y, Goldstein B, Monahan PE. Pipe SW, et al. Among authors: peerlinck k. N Engl J Med. 2023 Feb 23;388(8):706-718. doi: 10.1056/NEJMoa2211644. N Engl J Med. 2023. PMID: 36812434 Clinical Trial.
The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH.
Makris M, Oldenburg J, Mauser-Bunschoten EP, Peerlinck K, Castaman G, Fijnvandraat K; subcommittee on Factor VIII, Factor IX and Rare Bleeding Disorders. Makris M, et al. Among authors: peerlinck k. J Thromb Haemost. 2018 Dec;16(12):2530-2533. doi: 10.1111/jth.14315. Epub 2018 Nov 15. J Thromb Haemost. 2018. PMID: 30430726 Free article. No abstract available.
Ribosome dysfunction underlies SLFN14-related thrombocytopenia.
Ver Donck F, Ramaekers K, Thys C, Van Laer C, Peerlinck K, Van Geet C, Eto K, Labarque V, Freson K. Ver Donck F, et al. Among authors: peerlinck k. Blood. 2023 May 4;141(18):2261-2274. doi: 10.1182/blood.2022017712. Blood. 2023. PMID: 36790527 Free PMC article.
Emicizumab for acquired haemophilia A: A case series.
Engelen MM, Vandesande J, De Bent J, Van Laer C, Labarque V, Jacquemin M, Peerlinck K, Hermans C, Verhamme P, Vanassche T. Engelen MM, et al. Among authors: peerlinck k. Haemophilia. 2023 Jul;29(4):1049-1055. doi: 10.1111/hae.14809. Epub 2023 Jun 5. Haemophilia. 2023. PMID: 37276345
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
Pipe SW, Shima M, Lehle M, Shapiro A, Chebon S, Fukutake K, Key NS, Portron A, Schmitt C, Podolak-Dawidziak M, Selak Bienz N, Hermans C, Campinha-Bacote A, Kiialainen A, Peerlinck K, Levy GG, Jiménez-Yuste V. Pipe SW, et al. Among authors: peerlinck k. Lancet Haematol. 2019 Jun;6(6):e295-e305. doi: 10.1016/S2352-3026(19)30054-7. Epub 2019 Apr 16. Lancet Haematol. 2019. PMID: 31003963 Clinical Trial.
Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1.
O'Mahony B, Dunn AL, Leavitt AD, Peyvandi F, Ozelo MC, Mahlangu J, Peerlinck K, Wang JD, Lowe GC, Tan CW, Giermasz A, Tran H, Khoo TL, Cockrell E, Pepperell D, Chambost H, López Fernández MF, Kazmi R, Majerus E, Skinner MW, Klamroth R, Quinn J, Yu H, Wong WY, Robinson TM, Pipe SW. O'Mahony B, et al. Among authors: peerlinck k. J Thromb Haemost. 2023 Dec;21(12):3450-3462. doi: 10.1016/j.jtha.2023.08.032. Epub 2023 Sep 6. J Thromb Haemost. 2023. PMID: 37678546 Clinical Trial.
Pharmacotherapy with oral Xa inhibitors for venous thromboembolism.
Vanassche T, Vandenbriele C, Peerlinck K, Verhamme P. Vanassche T, et al. Among authors: peerlinck k. Expert Opin Pharmacother. 2015 Apr;16(5):645-58. doi: 10.1517/14656566.2015.999043. Epub 2015 Jan 2. Expert Opin Pharmacother. 2015. PMID: 25554350 Review.
Inhibitory and activating human antiplatelet antibodies.
Deckmyn H, Vanhoorelbeke K, Peerlinck K. Deckmyn H, et al. Among authors: peerlinck k. Baillieres Clin Haematol. 1998 Jun;11(2):343-59. doi: 10.1016/s0950-3536(98)80053-x. Baillieres Clin Haematol. 1998. PMID: 10097812 Review.
148 results